文献速递脊柱关节炎类风湿关节炎

托法替布对活动性银屑病关节炎TNFi应答不佳患者报告结局的影响:III期OPAL Beyond试验

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
PubMed 文献 · RMD Open · 2019-01-11

OPAL Beyond是一项6个月III期随机对照试验,纳入394例对肿瘤坏死因子抑制剂应答不佳的活动性银屑病关节炎患者,评估托法替布5mg或10mg每日两次对患者报告结局的影响。结果显示,治疗3个月时托法替布组在多个患者报告结局指标上显著优于安慰剂,且改善维持至6个月。

要点

  • 托法替布5mg和10mg每日两次在3个月时改善多个PRO指标,优于安慰剂。
  • 达到≥MCID改善的患者比例在多个PRO指标上显著高于安慰剂。
  • PRO改善在6个月时维持,且与OPAL Broaden试验中csDMARD-IR患者相似。

核心结论

  • 对TNFi应答不佳的PsA患者,托法替布治疗3个月在PROs上较安慰剂有统计学和临床意义的改善,并维持至6个月。

研究设计与样本

  • 6个月III期随机对照试验(OPAL Beyond,NCT01882439),纳入394例对TNFi应答不佳的活动性PsA患者,随机接受托法替布5mg或10mg每日两次或安慰剂(第3个月起转为托法替布)。

主要发现

  • 第3个月时,托法替布两个剂量组在PtGA、疼痛、PGJS、SF-36v2 PCS、PF、BP、活力、社会功能、FACIT-Fatigue总分、EQ-5D-3L疼痛/不适、EQ-VAS和ASQoL评分上均优于安慰剂(p≤0.05),RP仅10mg组优于安慰剂。
  • 达到≥MCID改善的患者比例在PtGA、PGJS、疼痛、ASQoL和SF-36v2 PCS、PF、RP、BP、SF上,托法替布两个剂量组均高于安慰剂(p≤0.05)。

关键数值与推荐

  • PRO改善定义为较基线变化≥MCID或评分≥规范值;名义p值未进行多重比较校正。

临床怎么用

  • 对于TNFi应答不佳的活动性PsA患者,托法替布可考虑用于改善患者报告的症状和生活质量。

局限性

  • 名义p值未进行多重比较校正;第3个月后安慰剂组转为托法替布,缺乏长期对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). Patient-reported outcomes (PROs) were evaluated in patients with PsA with inadequate responses to tumour necrosis factor inhibitors (TNFi-IR) in a 6-month, phase III randomised controlled trial (OPAL Beyond [NCT01882439]). METHODS: Patients (N=394) received tofacitinib 5 or 10 mg twice daily or placebo (advancing to tofacitinib 5 or 10 mg twice daily at month 3). Least squares mean changes from baseline and percentages of patients reporting improvements ≥minimum clinically important differences and scores ≥normative values were determined in Patient Global Assessment of disease activity (PtGA), Pain, Patient Global Joint and Skin Assessment (PGJS), Short Form-36 Health Survey version 2 (SF-36v2), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), EuroQol 5-Dimensions-3-level (EQ-5D-3L), EQ-VAS and Ankylosing Spondylitis Quality of Life (ASQoL). Nominal p values are without multiple comparison adjustments. RESULTS: At month 3, PtGA, Pain, PGJS, SF-36v2 Physical Component Summary (PCS), physical functioning (PF), bodily pain (BP), vitality and social functioning (SF) domains, FACIT-Fatigue Total score, EQ-5D-3L pain/discomfort, EQ-VAS and ASQoL scores exceeded placebo with both tofacitinib doses (role physical [RP] with 10 mg twice daily only; p≤0.05). Patients reporting improvements ≥MCID (%) in PtGA, PGJS, Pain, ASQoL and SF-36v2 PCS, PF, RP, BP, SF (both tofacitinib doses) exceeded placebo (p≤0.05). CONCLUSION: TNFi-IR patients with PsA receiving tofacitinib reported statistically and clinically meaningful improvements in PROs versus placebo over 3 months, which were maintained to month 6. Despite lower baseline scores, these improvements were similar to the csDMARD-IR TNFi-naive OPAL Broaden trial.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open. 2019. PMID: 30713722. doi:10.1136/rmdopen-2018-000808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。